In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied ...

The firm’s updated target reflects the $3 per share impact of the PIPE and its Buy rating reflects what it views as attractive risk/reward heading into 2025 neonatal Fc receptor updates.

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

Megakaryocytes (MKs), known for their role in platelet production, have emerged as critical players in immune responses, showcasing versatility in both physiological and pathological contexts.